Incidental Uptake of In-111 Ibritumomab Tiuxetan in Surgically Treated Fracture

Hidenari Hirata, Makoto Nakagawa, Koichiro Abe, Takashi Okafuji, Kenji Shinozaki, Ilseung Choi, Naokuni Uike, Shuji Sakai

Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University.
Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan.
Department of Radiology, National Kyushu Cancer Center, Fukuoka, Japan.

DOI: 10.4236/ami.2011.11002                

Abstract

In-111 ibritumomab tiuxetan pretherapy imaging is performed prior to radioimmunotherapy with Y-90 ibritumomab tiuxetan in patients with lymphoma in order to estimate the biodistribution of the radiolabeled antibodies. We report the case of a 61-year-old woman with relapsed follicular lymphoma. In-111 ibritumomab tiuxetan pretherapy imaging showed tracer accumulation in a surgically treated fracture of the left calcaneus as well as in the involved lesions. The patient had fractured her left calcaneus 6 months before the radioimmunotherapy, and fracture of the left calcaneus without lymphoma involvement had been revealed operatively at that time. Clinical features and magnetic resonance imaging (MRI) indicated an inflammatory response in the left heel. We concluded that this inflammation played an important role in the uptake on pretherapy imaging. It should be kept in mind that the inflammation is a differential diagnosis of lymphoma involvement in In-111 ibritumomab tiuxetan pretherapy imaging. To the best of our knowledge, this is the first case report of In-111 ibritumomab tiuxetan uptake in a surgically treated fracture.

Keywords

In-111, Ibritumomab, Fracture, Lymphoma

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	K. Tobinai, T. Watanabe, M. Ogura, Y. Morishima, T. Hotta, K. Ishizawa, K. Itoh, S. Okamoto, M. Taniwaki, N. Tsukamoto, H. Okumura, T. Terauchi, S. Nawano, M. Matsusako, Y. Matsuno, S. Nakamura, S. Mori, Y. Oha-shi, M. Hayashi and K. Endo, “Japanese Phase II Study of 90Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma,” Cancer Science, Vol. 100, No. 1, 2009, pp. 158-164.
[2]	S. J. Knox, M. L. Goris, K. Trisler, R. Negrin, T. Davis, T. M. Liles, A. Grillo-López, P. Chinn, C. Varns, S. C. Ning, S. Fowler, N. Deb, M. Becker, C. Marquez and R. Levy, “Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody Therapy of Recurrent B-Cell Lymphoma,” Clinical Cancer Research, Vol. 2, No. 3, 1996, pp. 457-470.
[3]	J. A. Narváez, J. Narváez, R. Ortega, C. Aguilera, A. Sánchez and E. Andía, “Painful Heel: MR Imaging Find-ings,” Radiographics, Vol. 20, No. 2, 2000, pp. 333-352.
[4]	W. A. Wegener, M. G. Velchik, D. Weiss, S. Ter, A. Byars, M. Neptune and A. Alavi, “Infectious Imaging with Indium-111-Labeled Nonspecific Polyclonal Human Immunoglobulin,” The Journal of Nuclear Medicine, Vol. 32, No. 11, 1991, pp. 2079-2085.
[5]	B. A. Sayle, H. D. Fawcett, W. M. Yudt, S. C. Wang, J. T. Mader and G. Cierny 3rd, “Indium-111 Chloride Imaging with Ununited Fractures,” Clinical Nuclear Medicine, Vol. 12, No. 3, 1987, pp. 208-209.
[6]	Ohta H, “In-111 Chloride Uptake in Ununited Fractures: A Case Report,” Kaku Igaku (Japanese Journal of Nuclear Medicine), Vol. 37, No. 2, 2000, pp. 121-124.
[7]	B. A. Sayle, S. Balachandran and C. A. Rogers, “In-dium-111 Chloride Imaging in Patients with Suspected Abscesses: Concise Communication,” The Journal of Nuclear Medicine, Vol. 24, No. 12, 1983, pp. 1114-1118.
[8]	R. A. Claessens,E. B. Koenders, O. C. Boerman, W. J. Oyen, G. F. Borm, J. W. van der Meer and F. H. Corstens, “Dissociation of Indium from Indium-111-labelled Die-thylene Triamine Penta-Acetic Acid Conjugated Non-Specific Polyclonal Human Immunoglobulin G in Inflammatory Foci,” European Journal of Nuclear Medi-cine, Vol. 22, No. 3, 1995, pp. 212-219.
[9]	M. Cremonesi, M. Ferrari, C. M. Grana, A. Vanazzi, M. Stabin, M. Bartolomei, S. Papi, G. Prisco, G. Martinelli, G. Paganelli and P. F. Ferrucci, “High-Dose Radioim-munotherapy with 90Y-Ibritumomab Tiuxetan: Compara-tive Dosimetric Study for Tailored Treatment,” The Journal of Nuclear Medicine, Vol. 48, No. 11, 2007, pp. 1871-1879.
[10]	P. C. Chinn, J. E. Leonard, J. Rosenberg, N. Hanna and D. R. Anderson, “Preclinical Evaluation of 90Y-Labeled Anti-CD20 Monoclonal Antibody for Treatment of Non-Hodgkin’s Lymphoma,” International Journal of Oncology, Vol. 15, No. 5, 1999, pp. 1017-1025.